99 DNA methylation testing for endometrial cancer detection in patient-friendly sample types 28. Bosschieter J, Bach S, Bijnsdorp I, Segerink L, Rurup WF, van Splunter A, et al. A protocol for urine collection and storage prior to DNA methylation analysis. PloS one. 2018;13(8):e0200906. 29. Liu B, Ricarte Filho J, Mallisetty A, Villani C, Kottorou A, Rodgers K, et al. Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020;26(16):4339-48. 30. Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences: Houghton Mifflin College Division; 2003. 31. Castor EDC. Castor Electronic Data Capture 2019 [27 Aug. 2019]. Available from: https:// castoredc.com. 32. Wang L, Dong L, Xu J, Guo L, Wang Y, Wan K, et al. Hypermethylated CDO1 and ZNF454 in Cytological Specimens as Screening Biomarkers for Endometrial Cancer. Front Oncol. 2022;12:714663. 33. Chang CC, Wang HC, Liao YP, Chen YC, Weng YC, Yu MH, et al. The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings. Journal of gynecologic oncology. 2018;29(1):e17. 34. De Strooper LM, van Zummeren M, Steenbergen RD, Bleeker MC, Hesselink AT, Wisman GB, et al. CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. Journal of clinical pathology. 2014;67(12):1067-71. 35. Herzog C, Marin F, Jones A, Evans I, Reisel D, Redl E, et al. A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets. J Clin Oncol. 2022:JCO2200266. 36. Schreiberhuber L, Herzog C, Vavourakis CD, Redl E, Kastner C, Jones A, et al. The WID(TM) -qEC test - performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. Int J Cancer. 2022. 37. Wen KC, Huang RL, Chen LY, Wu TI, Lu CH, Chu TY, et al. Endometrial Cancer Detection Using a Cervical DNA Methylation Assay (MPap) in Women with Abnormal Uterine Bleeding: A Multicenter Hospital-Based Validation Study. Cancers (Basel). 2022;14(17). 38. Nogueira-Costa G, Eiriz I, Braga S. Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities. Cancer Treat Res Commun. 2022;32:100581. 39. Jandaghi P, Hoheisel JD, Riazalhosseini Y. GHSR hypermethylation: a promising pan-cancer marker. Cell Cycle. 2015;14(5):689-90. 40. Yamashita K, Hosoda K, Nishizawa N, Katoh H, Watanabe M. Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment. Cancer Science. 2018;109(12):3695-706. 41. Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20(2):229-38. 42. Rohner E, McGuire FH, Liu Y, Li Q, Miele K, Desai SA, et al. Racial and Ethnic Differences in Acceptability of Urine and Cervico-Vaginal Sample Self-Collection for HPV-Based Cervical Cancer Screening. Journal of women’s health (2002). 2020;29(7):971-9. 4
RkJQdWJsaXNoZXIy MjY0ODMw